Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a fixed-dose **combination medication** containing three active ingredients: - **Ketorolac:** a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by non-selectively inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby decreasing the synthesis of prostaglandins involved in pain, inflammation, and fever[1][3][5][7]. - **Pitofenone:** a direct-acting smooth muscle relaxant structurally related to papaverine; it reduces spasms in smooth muscle of the gastrointestinal, urinary, and other organ systems[2]. - **Fenpiverinium:** an anticholinergic agent that relieves smooth muscle spasm by inhibiting muscarinic acetylcholine receptors on smooth muscle, leading to relaxation by blocking neural impulses[2][4][6]. This combination is primarily used for quick symptomatic relief of **acute pain associated with spasms** of smooth muscles, most commonly in the gastrointestinal and urinary tracts. The three agents act synergistically: ketorolac provides strong pain relief, while pitofenone and fenpiverinium reduce muscle spasm and associated pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + pitofenone + fenpiverinium.